A Field Efficacy Trial of Inactivated Hantaan Virus Vaccine (Hantavax(TM)) Against Hemorrhagic Fever with Renal Syndrome (HFRS) in the Endemic Areas of Yugoslavia from 1996 to 1998.
- Author:
Young Kyu CHU
1
;
Anna GLIGIC
;
Snezana TOMANOVIC
;
Boyana BOZOVJC
;
Mirceta OBRADOVIC
;
Young Dae WOO
;
Chang Nam AN
;
Hun KIM
;
Yang Seok JIANG
;
Seung Chul PARK
;
Min Ja KIM
;
Eun Il LEE
;
Ho Wang LEE
Author Information
1. WHO Collaborating Center for Virus Reference and Research (Hantaviruses).
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
HFRS;
Hantaan virus vaccine;
Field efficacy;
Hantavirus
- MeSH:
Adult;
Fever;
Hantaan virus*;
Hantavirus;
Hemorrhagic Fever with Renal Syndrome*;
Humans;
Mortality;
Prospective Studies;
Yugoslavia*
- From:Journal of the Korean Society of Virology
1999;29(2):55-64
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
In Yugoslavia, homorrhagic fever with renal syndrome (HFRS) is one of the important national health problem, but no vaccine has been used to prevent HFRS. Since first HFRS case in 1952, sporadic cases of HFRS occurred every year and over 4,000 registered cases with 1~16% mortality so far. We performed a prospective, randomized double-blind placebo-controlled trial to evaluate the effectiveness of Hantavax(TM) against HFRS in 3,900 healthy adults living in the endemic areas of Yugoslavia. 1,900 people were given 0.5 ml of Hantavax subcutaneously twice at one month interval and a booster shot at one year after. For controls other 2,000 healthy people were given 0.5 ml of physiolosical saline as a placebo. We investigated HFRS cases in both the vaccinated and nonvaccinated groups by monitoring the program for patient registration in the areas from 1996 to 1998, and the effect of vaccine was analyzed epidemiologically No confirmed case of HFRS was observed among 1,900 Hantavax vaccinees, while 20 confirmed cases were observed among 2,000 nonvaccinated control group. There were no remarkable side effects among the vaccinees either locally or in general after inoculation of the vaccine. The Hantavax vaccine showed statistically significant protective efficacy against HFRS among Yugoslavian people.
